In October 2019, Alexion entered into an asset purchase agreement with Immune Pharma to acquire an anti eotaxin-1 antibody for the development in inflammatory diseases. The agreement is pending completion due to bankruptcy proceedings, which are expected to conclude by the first quarter of 2020.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.